Gilead’s Kite building MD plant to support commercial CAR-Ts
A 20-acre site in Frederick, Maryland will support the production of Kite’s commercial CAR-T therapies, including Yescarta, from 2021. Kite, acquired by Gilead Sciences for US$11.9 billion in August 2017, is one of only two firms to so far see regulatory success for a chimeric antigen receptor ...
Chromatography and measurement company Waters Corporation experienced a volatile Q1 but its biopharma business remains high, backed by significan ...
Analytics and modeling tools can help deliver more effective and safer therapies to patients says Emerson, fresh from its acquisition of Bioprodu ...
Manufacturing constraints have led to supply issues concerning GlaxoSmithKline’s HPV vaccine, Cervarix, which are set to continue until June.
...
With continued double-digit growth in China and the future addition of GE Healthcare’s Biopharma business, Danaher Corporation is poised to str ...
Recent Tweets
-
RT @Dan5tanton: Kite expands manufacturing network: 20-acre site in Frederick, MD will support the production of #Gilead #Kite comm… https://t.co/lkynirnQzj
1 day ago
-
RT @Dan5tanton: Chromatography and measurement company Waters Corporation experienced a volatile Q1 but its biopharma business rema… https://t.co/WxVZFm9ogU
1 day ago
-
RT @Dan5tanton: The US Biomedical Advanced Research and Development Authority ( #BARDA ) will use Enesi Pharma’s ImplaVax device an… https://t.co/v6XhAo33hk
1 week ago
-
BREAKING NEWS - more consolidation in gene therapy CMO space https://t.co/DCz8eUuaTQ
2 weeks ago
Trending
Upstream Processing
Monoclonal Antibodies: Beyond the Platform in Manufacturing
Manufacturing
Antibody Derivatives: Deconstructing MAbs for the Next Wave of Biotherapies
2019
2019 BioProcess International West Event Report
Analytical Upstream Processing
Visible Particulate Matter in Single-Use Bags: From Measurement to Prevention